Literatur

1. Ramiro S, Nikiphorou E, Sepriano A, Ortolan A, Webers C, Baraliakos X et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2023; 82(1): 19–34.

2. Deodhar A, Van den Bosch F, Poddubnyy D, Maksymowych WP, van der Heijde D, Kim TH et al. Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2022; 400(10349): 369–379.

3. van der Heijde D, Baraliakos X, Sieper J, Deodhar A, Inman RD, Kameda H et al. Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial. Ann Rheum Dis. 2022; 81(11): 1515–1523.

4. van der Heijde D, Deodhar A, Baraliakos X, Brown MA, Dobashi H, Dougados M et al. Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials. Ann Rheum Dis. 2023; 82(4): 515–526.

5. Coates LC, Soriano ER, Corp N, Bertheussen H, Callis Duffin K, Campanholo CB et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022; 18(8): 465–479.

6. Lubrano E, Chan J, Queiro-Silva R, Cauli A, Goel N, Poddubnyy D et al. Management of Axial Disease in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations. J Rheumatol. 2023; 50(2): 279–284.

7. Baraliakos X, Ranza R, Ostor A, Ciccia F, Coates LC, Rednic S et al. Efficacy and safety of upadacitinib in patients with active psoriatic arthritis and axial involvement: results from two phase 3 studies. Arthritis Res Ther. 2023; 25(1): 56.

8. Kristensen LE, Strober B, Poddubnyy D, Leung YY, Jo H, Kwok K et al. Association between baseline cardiovascular risk and incidence rates of major adverse cardiovascular events and malignancies in patients with psoriatic arthritis and psoriasis receiving tofacitinib. Therapeutic advances in musculoskeletal disease. 2023; 15: 1759720X221149965.

9. Burmester GR, Cohen SB, Winthrop KL, Nash P, Irvine AD, Deodhar A et al. Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis. RMD open. 2023; 9(1): e002735.

10. McInnes IB, Asahina A, Coates LC, Landewe R, Merola JF, Ritchlin CT et al. Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL). Lancet. 2023; 401(10370): 25–37.

11. Merola JF, Landewe R, McInnes IB, Mease PJ, Ritchlin CT, Tanaka Y et al. Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-alpha inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE). Lancet. 2023; 401(10370): 38–48.